We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-10%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.64B
AUM Growth
-$98.2M
Cap. Flow
+$187M
Cap. Flow %
11.36%
Top 10 Hldgs %
46.02%
Holding
79
New
7
Increased
13
Reduced
45
Closed
4

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.9M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$23.3M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$18.4M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$18.2M
5
QURE icon
uniQure
QURE
+$17.3M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$20.8M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$15.6M
3
ALLK
Allakos
ALLK
+$13.6M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$11.3M
5
ANAB icon
AnaptysBio
ANAB
+$5.18M

Sector Composition

Rank Sector Weight
1 Healthcare 82.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
YMAB
26
DELISTED
Y-mAbs Therapeutics
YMAB
$23M 1.4%
883,800
-116,200
-12% -$2.97M
LKFT
27
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$22.9M 1.39%
150,000
-25,000
-14% -$4.1M
ANAB icon
28
AnaptysBio
ANAB
$1.63B
$20.7M 1.26%
591,200
-108,800
-16% -$5.18M
AMRN
29
Amarin Corp
AMRN
$304M
$20.2M 1.23%
66,600
+41,600
+166% +$14.5M
EIDX
30
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$19.4M 1.18%
540,686
-11,235
-2% -$439K
KURA icon
31
Kura Oncology
KURA
$817M
$18.7M 1.14%
1,231,500
-168,500
-12% -$3M
AKRO
32
DELISTED
Akero Therapeutics
AKRO
$16.8M 1.03%
740,621
-27,221
-4% -$633K
SRPT icon
33
Sarepta Therapeutics
SRPT
$1.68B
$16.7M 1.02%
221,700
-3,300
-1% -$390K
TWST icon
34
Twist Bioscience
TWST
$7.21B
$16.4M 1%
687,149
-18,915
-3% -$550K
MRTX
35
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$15.6M 0.95%
200,000
– –
ARGX icon
36
argenx
ARGX
$54.3B
$14.6M 0.89%
128,110
-21,890
-15% -$2.96M
NKTR icon
37
Nektar Therapeutics
NKTR
$2.47B
$14.4M 0.87%
52,587
+25,920
+97% +$9.51M
STSA
38
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$12.9M 0.78%
+858,382
New +$13.3M
SAGE
39
DELISTED
Sage Therapeutics
SAGE
$12.4M 0.76%
88,700
-11,300
-11% -$1.89M
CCXI
40
DELISTED
ChemoCentryx, Inc.
CCXI
$12.3M 0.75%
1,820,000
-545,280
-23% -$4.09M
HSACU
41
DELISTED
Health Sciences Acquisitions Corporation Units
HSACU
$11.6M 0.71%
1,080,000
– –
XFOR icon
42
X4 Pharmaceuticals
XFOR
$391M
$11.2M 0.68%
29,389
-291
-1% -$115K
INSP icon
43
Inspire Medical Systems
INSP
$1.74B
$10.5M 0.64%
172,300
-27,700
-14% -$1.82M
GOSS icon
44
Gossamer Bio
GOSS
$86.9M
$10.4M 0.63%
618,129
-25,000
-4% -$497K
EIGR
45
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$10.2M 0.62%
33,263
-5,070
-13% -$1.65M
ZLAB icon
46
Zai Lab
ZLAB
$2.07B
$8.97M 0.55%
277,161
-22,839
-8% -$784K
HARP
47
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$8.88M 0.54%
64,999
– –
TECX
48
Tectonic Therapeutic
TECX
$558M
$8.02M 0.49%
47,358
+24,441
+107% +$5.53M
ORTX
49
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$8.02M 0.49%
67,533
-5,500
-8% -$768K
ARNA
50
DELISTED
Arena Pharmaceuticals Inc
ARNA
$7.89M 0.48%
172,300
-27,700
-14% -$1.56M
1
2
3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q3 2019 Portfolio in Review

As of Q3 2019, Cormorant Asset Management held 79 positions worth $1.64B, down 5.6% from $1.74B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Cormorant Asset Management deployed $187M of net new capital in Q3 2019, opening 7 new positions and adding to 13 existing holdings. Its largest new stake was Deciphera Pharmaceuticals, Inc. Common Stock: 788,500 shares worth $26.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 89% a quarter earlier.

On the sell side, the largest reduction was Allakos, an estimated $13.6M trimmed.

  • Cormorant Asset Management's largest Q3 2019 buy was Deciphera Pharmaceuticals, Inc. Common Stock: 788,500 shares worth $26.8M.
  • Cormorant Asset Management added most to Mirati Therapeutics, Inc. Common Stock in Q3 2019, an estimated $46.9M increase.
  • Cormorant Asset Management's biggest Q3 2019 reduction was Allakos, cutting an estimated $13.6M.
  • Cormorant Asset Management fully exited Array Biopharma Inc in Q3 2019, selling an estimated $20.8M.
  • Cormorant Asset Management's ten largest holdings make up 46% of its $1.64B portfolio in Q3 2019.
  • Cormorant Asset Management opened 7 new positions and closed 4 in Q3 2019.
  • Cormorant Asset Management's portfolio value fell 5.6% quarter-over-quarter to $1.64B.

Based on Cormorant Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.